Empagliflozin Ameliorates Diabetic Cardiomyopathy via Attenuating Oxidative Stress and Improving Mitochondrial Function

Diabetic cardiomyopathy (DCM) is considered to be a critical contributor to the development of heart failure. Empagliflozin (EMPA), a sodium-glucose cotransporter 2 inhibitor, has been shown to prevent cardiovascular events and reduce the incidence of heart failure in randomized clinical trials. How...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jinwu, Huang, Xinyuan, Liu, Hanjie, Chen, Yuhang, Li, Peipei, Liu, Lingling, Li, Jiashen, Ren, Yangxi, Huang, Junping, Xiong, Erya, Tian, Zhijie, Dai, Xiaozhen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9110219/
https://www.ncbi.nlm.nih.gov/pubmed/35585884
http://dx.doi.org/10.1155/2022/1122494

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9110219/
https://www.ncbi.nlm.nih.gov/pubmed/35585884
http://dx.doi.org/10.1155/2022/1122494

Ejemplares similares